- Home
- GEG vs RAPT Comparison
GEG vs RAPT Comparison
Compare GEG & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- RAPT
- Stock Information
- Founded
- GEG 1994
- RAPT 2015
- Country
- GEG United States
- RAPT United States
- Employees
- GEG N/A
- RAPT N/A
- Industry
- GEG Computer Software: Prepackaged Software
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GEG Technology
- RAPT Health Care
- Exchange
- GEG Nasdaq
- RAPT Nasdaq
- Market Cap
- GEG 57.3M
- RAPT 65.6M
- IPO Year
- GEG N/A
- RAPT 2019
- Fundamental
- Price
- GEG $1.78
- RAPT $1.52
- Analyst Decision
- GEG
- RAPT Hold
- Analyst Count
- GEG 0
- RAPT 10
- Target Price
- GEG N/A
- RAPT $5.00
- AVG Volume (30 Days)
- GEG 20.5K
- RAPT 920.1K
- Earning Date
- GEG 11-11-2024
- RAPT 11-12-2024
- Dividend Yield
- GEG N/A
- RAPT N/A
- EPS Growth
- GEG N/A
- RAPT N/A
- EPS
- GEG N/A
- RAPT N/A
- Revenue
- GEG $18,516,000.00
- RAPT N/A
- Revenue This Year
- GEG N/A
- RAPT N/A
- Revenue Next Year
- GEG N/A
- RAPT N/A
- P/E Ratio
- GEG N/A
- RAPT N/A
- Revenue Growth
- GEG 83.09
- RAPT N/A
- 52 Week Low
- GEG $1.70
- RAPT $1.25
- 52 Week High
- GEG $2.12
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- GEG 45.61
- RAPT 39.12
- Support Level
- GEG $1.75
- RAPT $1.31
- Resistance Level
- GEG $1.81
- RAPT $1.96
- Average True Range (ATR)
- GEG 0.06
- RAPT 0.37
- MACD
- GEG 0.00
- RAPT -0.09
- Stochastic Oscillator
- GEG 50.00
- RAPT 10.67
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.